studynumber,id,arm,year,drug,n,qtcm,qtcsd,qtcn,qtcextraction,qtcsdorigin,FullStudyName,corr_auth,corr_auth_email,other_email,answer_after_1_mail,bibkey,treatment
4686,Ishigooka 2018,78381,2018,Placebo,116,,,,,,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,,,,,,Ishigooka2018,active
2798,Litman 2016,7675,2016,Placebo,55,,,,,,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,,,,,,Litman2016,active
331,NCT01104766a,700,2015,Placebo,153,,,,,,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,,,,,,Durgam2015,active
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,,,,,,Durgam2015,active
978,Lieberman 2015,3198,2015,Placebo,85,,,,,,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,,,,,,Lieberman2015,active
1033,Kane 2015,3340,2015,Placebo,184,3.5,18,168,change,original,,,,,,Kane2015a,control
1033,Kane 2015,76209,2015,Brexpiprazole,370,1.21420454545455,17.513891319178,352,change,original,,,,,,Kane2015a,active
1056,Correll 2015,3392,2015,Placebo,184,0.9,18.5,170,change,original,,,,,,Correll2015,control
1056,Correll 2015,76210,2015,Brexpiprazole,362,0.222448979591837,15.7762754256417,343,change,original,,,,,,Correll2015,active
1406,NCT01098110,4158,2015,Placebo,174,,,,,,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,,,,,,Kinoshita2016,active
1408,NCT01617187a,4163,2015,Asenapine,113,,,,,,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,,,,,,Landbloom2017,control
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,,,,,,Landbloom2017,active
1415,NCT00905307a,4180,2015,Aripiprazole,50,,,,,,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,,,,,,Kane2016,control
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,,,,,,Kane2016,active
3017,Loebel 2015a,7985,2015,Lurasidone,199,,,,,,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,,,,,,Loebel2016,control
280,Litmann 2014,591,2014,Placebo,41,,,,,,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,,,,,,Litman2014,active
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,,,,,,Schmidt2014,active
601,Shen 2014,2965,2014,Placebo,78,,,,,,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,,,,,,Shen2014,active
649,Durgam 2014a,2423,2014,Placebo,151,-1.4,24.757979667836,151,change,sd estimated from mean of SDs,,,,,,Durgam2014,control
649,Durgam 2014a,2424,2014,Risperidone,140,5.1,24.757979667836,140,change,sd estimated from mean of SDs,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active
649,Durgam 2014b,76207,2014,Cariprazine,438,-1.9675799086758,24.757979667836,438,change,sd estimated from mean of SDs,,,,,,Durgam2014,active
674,Geffen 2012,2476,2012,Risperidone,91,,,,,,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active
674,Geffen 2012,2475,2012,Placebo,93,,,,,,,,,,,Geffen2012,control
245,Kinon 2011,505,2011,Olanzapine,62,,,,,,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active
245,Kinon 2011,506,2011,Placebo,122,,,,,,,,,,,Kinon2011,control
235,Kane 2010a,483,2010,Haloperidol,115,,,,,,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active
235,Kane 2010a,484,2010,Placebo,123,,,,,,,,,,,Kane2010,control
235,Kane 2010b,482,2010,Asenapine,220,,,,,,,,,,,Kane2010,active
403,Study 006,902,2010,Lurasidone,99,-0.1,22.09,98,change,original,,,,,,Ogasa2013,active
403,Study 006,903,2010,Placebo,50,2.2,21.24,49,change,original,,,,,,Ogasa2013,control
404,Study 049a,904,2010,Haloperidol,73,2.1,20.3,66,change,original,,,,,,Potkin2015,active
404,Study 049a,906,2010,Placebo,72,-1.8,19,68,change,original,,,,,,Potkin2015,control
404,Study 049b,905,2010,Lurasidone,140,-0.4,21.71,132,change,original,,,,,,Potkin2015,active
891,Study 196,2996,2010,Placebo,90,5.4,20,90,change,original,,,,,,Nakamura2009,control
891,Study 196,2995,2010,Lurasidone,90,3.3,20.4,90,change,original,,,,,,Nakamura2009,active
892,Study 229,2997,2010,Lurasidone,372,2,22.6,359,change,original,,,,,,Nasrallah2013,active
892,Study 229,2998,2010,Placebo,128,2.2,22.8,120,change,original,,,,,,Nasrallah2013,control
893,Study 231a,3001,2010,Placebo,116,9,20.6,109,change,original,,,,,,Meltzer2011,control
893,Study 231a,3000,2010,Olanzapine,123,10,21.6,121,change,original,,,,,,Meltzer2011,active
893,Study 231b,2999,2010,Lurasidone,239,4.4,20.6,227,change,original,,,,,,Meltzer2011,active
894,Study 233a,3003,2010,Placebo,122,7.6,19,113,change,original,,,,,,Harvey2013,control
894,Study 233a,3004,2010,Quetiapine,120,10.4,17.6,107,change,original,,,,,,Harvey2013,active
894,Study 233b,3002,2010,Lurasidone,246,2.9,20.67,225,change,original,,,,,,Harvey2013,active
163,Garcia 2009,324,2009,Haloperidol,60,3.03,26.48,60,change,original,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active
163,Garcia 2009,325,2009,Placebo,64,6.1,20.39,64,change,original,,,,,,Garcia2009,control
190,Hera 041-021a,383,2009,Asenapine,208,,,,,,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active
190,Hera 041-021a,385,2009,Placebo,106,,,,,,,,,,,Hera2009a,control
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,,,,,,Hera2009a,active
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,,,,,,Hera2009b,active
191,Hera 041-022,388,2009,Placebo,93,,,,,,,,,,,Hera2009b,control
65,Casey 2008,146,2008,Risperidone,120,,,,,,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active
65,Casey 2008,145,2008,Placebo,119,,,,,,,,,,,Casey2008,control
633,Cutler 2008a,2382,2008,Ziprasidone,151,6.1,18.6,148,change,original,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active
633,Cutler 2008a,2299,2008,Placebo,152,-2,18.2,141,change,original,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control
633,Cutler 2008b,2298,2008,Iloperidone,303,7.2,20.2,288,change,original,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active
722,Johnson NCT00397033,2590,2008,Paliperidone,209,,,,,,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,,,,,,Canuso2010a,control
723,Johnson NCT00412373,2593,2008,Placebo,95,,,,,,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,,,,,,Canuso2010b,active
724,Johnson NCT00524043,2594,2008,Paliperidone,70,,,,,,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,,,,,,Coppola2011,control
776,Lindenmayer 2008,2710,2008,Quetiapine,267,1.4,20.4,213,change,original,,,,,,Lindenmayer2008,active
776,Lindenmayer 2008,2709,2008,Placebo,84,-2.7,16.6,66,change,original,,,,,,Lindenmayer2008,control
895,Study 3000a,3007,2008,Placebo,127,-0.3,19.3,116,change,original,,,,,,Potkin2008,control
895,Study 3000a,3005,2008,Haloperidol,124,1.4,20.5,110,change,original,,,,,,Potkin2008,active
895,Study 3000b,3006,2008,Iloperidone,124,0.1,20.2,113,change,original,,,,,,Potkin2008,active
899,Study 3004a,3015,2008,Placebo,156,1.2,19.6,147,change,original,,,,,,Potkin2008,control
899,Study 3004a,3014,2008,Iloperidone,154,5,19,145,change,original,,,,,,Potkin2008,active
899,Study 3004b,3016,2008,Risperidone,153,2.4,20.2,136,change,original,,,,,,Potkin2008,active
900,Study 3005a,3019,2008,Risperidone,157,1.1,22.9,138,change,original,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active
900,Study 3005a,3018,2008,Placebo,160,-2.5,21.3,143,change,original,,,,,,Potkin2008,control
900,Study 3005b,3017,2008,Iloperidone,389,6.1,20.6,323,change,original,,,,,,Potkin2008,active
965,Study RGH-MD-03,3162,2008,Placebo,130,,,,,,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,,,,,,Durgam2016,active
992,Cutler 2008a,3239,2008,Placebo,117,-1.79,24.757979667836,117,change,sd estimated from mean of SDs,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control
992,Cutler 2008a,76208,2008,Quetiapine,448,1.2575,24.757979667836,447,change,sd estimated from mean of SDs,,,,,,Cutler2010,active
129,Davidson 2007a,255,2007,Placebo,123,,,,,,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,,,,,,Davidson2007,active
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,,,,,,Davidson2007,active
227,Kahn 2007,464,2007,Placebo,118,,,,,,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,,,,,,Kahn2007,active
307,McEvoy 2007b,649,2007,Aripiprazole,206,,,,,,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,,,,,,McEvoy2007,control
313,Meltzer 2007a,661,2007,Placebo,149,,,,,,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,,,,,,Meltzer2007,active
734,Kane 2007b,2617,2007,Placebo,127,,,,,,,,,,,Kane2007,control
734,Kane 2007b,2615,2007,Olanzapine,128,,,,,,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,,,,,,Kane2007,active
789,Marder 2007c,2739,2007,Placebo,110,0.5,15.37,105,change,original,,,,,,Marder2007,control
789,Marder 2007c,2738,2007,Paliperidone,224,0.35,13.34,222,change,original,,,,,,Marder2007,active
789,Marder 2007d,2737,2007,Olanzapine,110,1.9,16.7,105,change,original,,,,,,Marder2007,active
829,Patil 2007,2830,2007,Olanzapine,34,4.16,24.757979667836,28,change,sd estimated from mean of SDs,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active
829,Patil 2007,2831,2007,Placebo,63,1.61,24.757979667836,27,change,sd estimated from mean of SDs,,,,,,Patil2007,control
845,Potkin 2007d,2866,2007,Placebo,62,-1.6,18,58,change,original,,,,,,Potkin2007,control
845,Potkin 2007d,2867,2007,Risperidone,60,4.4,16.8,57,change,original,,,,,,Potkin2007,active
845,Potkin 2007c,2865,2007,Asenapine,60,4.6,18.5,57,change,original,,,,,,Potkin2007,active
843,Potkin 2003a,2859,2003,Aripiprazole,202,-0.67,22.4,194,change,original,,,,,,Potkin2003,active
843,Potkin 2003a,2860,2003,Placebo,103,-2.18,22.6,103,change,original,,,,,,Potkin2003,control
843,Potkin 2003b,2861,2003,Risperidone,99,6.31,22.4,95,change,original,,,,,,Potkin2003,active
231,Kane 2002b,473,2002,Haloperidol,104,1.67,24.757979667836,104,change,sd estimated from mean of SDs,,,,,,Kane2002,active
418,Study 94202 2002a,940,2002,Aripiprazole,61,-6.6,24,57,change,p-value,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active
418,Study 94202 2002a,942,2002,Placebo,64,-4.5,24,61,change,p-value,,,,,,Study942022002,control
418,Study 94202 2002b,941,2002,Haloperidol,63,-0.7,24,57,change,p-value,,,,,,Study942022002,active
405,Study 115 2000a,908,2000,Placebo,83,406.2,22.1,75,endpoint,original,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control
405,Study 115 2000a,909,2000,Ziprasidone,164,422.6,29.59,156,endpoint,original,,,,,,Study1152000,active
405,Study 115 2000b,907,2000,Haloperidol,85,410.2,19.4,79,endpoint,original,,,,,,Study1152000,active
127,Daniel 1999,249,1999,Placebo,92,413.3,40.7,84,endpoint,original,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control
127,Daniel 1999,250,1999,Ziprasidone,104,417.2,23.6,102,endpoint,original,,,,,,Daniel1999,active
14,Arvanitis 1997a,31,1997,Placebo,51,-5,24.757979667836,51,change,sd estimated from mean of SDs,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control
14,Arvanitis 1997a,32,1997,Quetiapine,105,2.86,24.757979667836,105,change,sd estimated from mean of SDs,,,,,,Arvanitis1997,active
14,Arvanitis 1997b,30,1997,Haloperidol,52,4,24.757979667836,52,change,sd estimated from mean of SDs,,,,,,Arvanitis1997,active
611,Small 1997,2988,1997,Quetiapine,96,,,,,,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active
611,Small 1997,2987,1997,Placebo,96,,,,,,,,,,,Small1997,control
946,Zimbroff 1997a,3123,1997,Sertindole,144,20.85,31,117,change,original,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active
946,Zimbroff 1997a,3122,1997,Placebo,73,-6.9,19.13,60,change,original,,,,,,Zimbroff1997,control
946,Zimbroff 1997b,3121,1997,Haloperidol,137,1.48,23.3,176,change,original,,,,,,Zimbroff1997,active
31,Beasley 1996a,70,1996,Placebo,50,,,,,,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,,,,,,Beasley1996a,active
32,Beasley 1996b,71,1996,Haloperidol,69,1.76,25.52,54,change,original,,,,,,Beasley1996b,active
32,Beasley 1996b,73,1996,Placebo,68,-1.77,19.38,54,change,original,,,,,,Beasley1996b,control
32,Beasley 1996c,72,1996,Olanzapine,133,2.73,27.43,109,change,original,,,,,,Beasley1996b,active
560,Borison 1996,2271,1996,Placebo,55,-0.1,24.757979667836,55,change,sd estimated from mean of SDs,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control
560,Borison 1996,2272,1996,Quetiapine,54,7.2,24.757979667836,54,change,sd estimated from mean of SDs,,,,,,Borison1996,active
923,van Kammen 1996,3070,1996,Sertindole,105,20.04,21.72,91,change,original,,,,,,VanKammen1996,active
923,van Kammen 1996,3069,1996,Placebo,48,-0.34,11.33,41,change,original,,,,,,VanKammen1996,control
942,Zborowski 1995a,3113,1995,Placebo,116,-0.85,24.18,78,change,original,,,,,,Zborowski1995,control
942,Zborowski 1995a,3112,1995,Haloperidol,115,-5.23,29.51,90,change,original,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active
942,Zborowski 1995b,3114,1995,Sertindole,117,24.84,28.53,93,change,original,,,,,,Zborowski1995,active
84,Clark 1972a,191,1972,Chlorpromazine,19,,,,,,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active
84,Clark 1972a,193,1972,Placebo,18,,,,,,,,,,,Clark1972,control
84,Clark 1972b,192,1972,Loxapine,18,,,,,,,,,,,Clark1972,active
591,Clark 1970a,2326,1970,Chlorpromazine,15,,,,,,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active
591,Clark 1970a,2328,1970,Placebo,14,,,,,,Pharmacology & Therapeutics 1970,,,,,Clark1970,control
